Abbott Capitulates In Continuous Glucose Deal: Can SpectRx Go It Alone?
This article was originally published in The Gray Sheet
Executive Summary
SpectRx likely will have to find another development partner for FDA pivotal studies of its consumer continuous glucose monitoring device after initiating termination of a joint R&D and license agreement with Abbott Laboratories Jan. 7